ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity
Several other brokerages have also issued reports on ANIP. Zacks Investment Research upgraded ANI Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, July 5th. BidaskClub upgraded ANI Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 18th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $67.33.
Shares of ANI Pharmaceuticals (ANIP) traded up $1.54 during midday trading on Thursday, reaching $63.51. The company’s stock had a trading volume of 173,551 shares, compared to its average volume of 124,398. The firm has a market cap of $731.24, a price-to-earnings ratio of 18.50 and a beta of 2.84. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $65.81.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $48.16 million during the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.09 EPS. equities research analysts forecast that ANI Pharmaceuticals will post 3.52 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/ani-pharmaceuticals-inc-anip-given-buy-rating-at-canaccord-genuity/1683776.html.
Institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 44.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 664 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $204,000. Municipal Employees Retirement System of Michigan raised its stake in shares of ANI Pharmaceuticals by 132.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 2,390 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $226,000. Finally, Stevens Capital Management LP bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $207,000. Institutional investors and hedge funds own 55.55% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.